KLOW and GLOW: what's in each blend and what's known
Reviewed 26 sourcesPublished by PepVault
KLOW and GLOW: the peptides in each vial and the label amounts, why no trial has tested either blend, and what is measured for each part, with the species.

- Last reviewed
- Sources
- 26
- Questions
- 10
- Compounds
- 5
The short answer
GLOW is three peptides sold in one vial: GHK-Cu, BPC-157 and TB-500, commonly labelled 50, 10 and 10 mg. KLOW is the same vial with 10 mg of KPV added. No trial has tested either blend, so what is known comes from each part on its own: mostly animal and cell studies, a few small skin trials of GHK-Cu, and eye-drop trials of TB-500's parent protein.
Evidence: No study has tested KLOW or GLOW as a blend. Each part has mostly animal and cell research; in people, small topical trials of GHK-Cu, eye-drop, gel and IV trials of thymosin beta-4 (not TB-500), three small uncontrolled BPC-157 pilots and none for KPV.

What is in KLOW and GLOW?
Both are community formulas: a set of peptides freeze-dried together in one vial and sold under a short name. GLOW has three parts and KLOW has four. The amounts below are the ones the blends are commonly labelled with, and the ones PepVault's library lists. They describe what is in the whole vial, not a dose.
| Part | What it is | GLOW vial | KLOW vial |
|---|---|---|---|
| GHK-Cu | Three amino acids holding a copper ion | 50 mg | 50 mg |
| BPC-157 | 15 amino acids, a piece of a gastric juice protein | 10 mg | 10 mg |
| TB-500 | A seven-amino-acid piece of thymosin beta-4 | 10 mg | 10 mg |
| KPV | Three amino acids from the hormone alpha-MSH | None | 10 mg |
| Total | 70 mg | 80 mg |

Two things stand out. GHK-Cu is most of either vial by weight: five times as much as each other part, about 71% of GLOW and 63% of KLOW. And because every part is mixed at a fixed ratio, any amount drawn from the vial carries all of them in that same ratio. Vendors' labels vary, so the vial's own label is the one to read.

Has anyone tested KLOW or GLOW as a blend?
No. We found no paper in PubMed that tests either blend, or GHK-Cu with KPV, BPC-157 and TB-500 together, and no record of one on ClinicalTrials.gov (searched November 20, 2026). Everything said about the blends is borrowed from studies of the parts, one at a time.
The closest test covers two of the parts: in 32 rats with repaired Achilles tendons, BPC-157 plus TB-500 did no better than either alone, and only TB-500 alone made the tendons significantly stronger1. Our guide to BPC-157 and TB-500 walks through it. No study has asked what GHK-Cu or KPV adds.
What has been measured for each part?
Here is each part's strongest measured result, and who it was measured in. Most of it is animal and cell work; where a human trial exists, it tested the part alone, and often by a different route than an injection.
| Part | What was measured | In whom |
|---|---|---|
| BPC-157 | Faster return of blood flow and more vessels in a blocked leg artery4; tendon cells that moved further and survived stress better5 | Rats; rat cells and human vessel cells in a dish |
| BPC-157 | Knee pain relief reported by phone, in a chart review with no comparison group: one of three small BPC-157 pilots in people23 | 16 people, 4 of them also given thymosin beta-4 |
| TB-500's parent, thymosin beta-4 | Wounds covered over up to 61% more than with saline by day 76 | Rats |
| LKKTETQ, the stretch TB-500 copies | Skin wounds repaired about as well as with the whole protein7 | Aged mice |
| Thymosin beta-4 eye drops (RGN-259) | Mixed: wins in small trials, no clear difference in the two largest (below) | People with dry eye or a corneal defect |
| GHK-Cu | More collagen made by skin cells, peaking at a nanomolar level19 | Cells in a dish |
| GHK-Cu gel | Diabetic foot ulcers closed further than with a plain gel (median 98.5% vs 60.8%)20 | People, on the skin |
| KPV | Less gut inflammation and faster recovery from two kinds of colitis2223 | Mice; human gut and immune cells in a dish |

Species note: a rat tendon, a mouse colon or a cell in a dish shows what a peptide can do to the machinery of repair. It does not show what an injection of the blend does in a person.
What is KPV, the part KLOW adds?
KPV is three amino acids, lysine, proline and valine, the last three links of alpha-MSH, a hormone whose jobs include damping inflammation23. Picture three beads on a string; the Peptide Sky below draws it that way.
Peptide SkySee KPV as a molecule53 peptides as a night sky in 3D. Each star opens into its molecule, one bead per amino acid, with the measured shape where one exists.Open the Peptide SkyIts record is about the gut. In human gut-lining and immune cells in a dish, nanomolar amounts of KPV blocked NF-kappaB, a main switch for inflammatory signals, and cut inflammatory cytokines. It got into the cells through PepT1, a transporter that carries small peptides, and given in drinking water it eased two kinds of chemically caused colitis in mice22. A second team found KPV-treated mice with colitis recovered earlier, regained more weight and had fewer inflammatory cells in the colon; in mice without a working MC1R, the receptor alpha-MSH acts through, every treated animal survived the colitis23. Packed into nanoparticles and given by mouth, it helped the colon lining heal in mice24.
We found no published human study of KPV by any route, and the FDA says it has not identified any human exposure data for it25. So in KLOW, KPV is the part with the least human data of all.
Is the TB-500 in the vial the same as thymosin beta-4?
No. Thymosin beta-4 is a natural protein of 43 amino acids17. Anti-doping chemists who analysed a product sold as TB-500 found Ac-LKKTETQ: its seven-amino-acid stretch at positions 17 to 23, with an acetyl group added to one end8. In fibroblasts in a dish, one of TB-500's breakdown pieces sped wound closing and TB-500 itself did not9, and a 2026 orthopaedic review warns that the two are often treated as one with no proof that they are equivalent10. Our guide to BPC-157 and TB-500 covers that lab work.
That matters because the human trials belong to the full protein, given as eye drops, a gel or an IV, never as TB-500:

- Dry eye. In a 9-patient trial, the drops cut discomfort by 35.1% more than a plain solution at day 5611. A 72-person trial missed both main goals but won on some secondary ones12. In the two largest, ARISE-2 (601 people) and ARISE-3 (700), the posted results show the drops and placebo moving the main measures by almost the same amount1314.
- A non-healing corneal defect. In a phase 3 trial, 6 of 10 eyes on the drops healed fully by 4 weeks, against 1 of 8 on placebo, a trend that fell just short of significance15.
- Skin. In a terminated trial for epidermolysis bullosa, a blistering skin disease, wounds healed in 8 of 22 patients on the gel and 5 of 8 on placebo, a larger share on placebo but not a significant difference16. In 73 people with venous leg ulcers, the gel's safety was comparable to placebo17.
- IV safety. In a placebo-controlled trial in 40 healthy volunteers, daily IV doses for 14 days were well tolerated, with no serious adverse events18.
What does GHK-Cu bring to the vial?
GHK-Cu is the skin part of the vial. In cells, it raised collagen production at tiny concentrations19. In people, its controlled trials put it on the skin: a gel that helped diabetic foot ulcers close20, and the only two randomized trials a 2026 systematic review found for aesthetic use21. Our guide to GHK-Cu for skin and hair covers those trials.
In KLOW and GLOW it is injected, and that route has no trial of its own. For injectable GHK-Cu, the FDA notes that there are limited data in humans to inform safety25.
What do people who use KLOW or GLOW report?
Commonly reported: with GLOW, firmer and smoother skin over one to two months, and small injuries and procedures healing faster; with KLOW, a calmer gut within a few weeks, then nagging tendon pain easing. Redness or a small itchy bump where the needle went in is the most common complaint, and it fades on its own.
These are user reports, not trial results. They line up with each part's own studies, skin for GHK-Cu, gut for KPV and repair for BPC-157 and TB-500, but no study has compared a blend with its parts.
When to get help If redness at the site keeps spreading, turns hot and painful, or comes with a fever, have a doctor look at it the same day.
How can you tell what the blend is doing for you?
A blend starts every part on the same day, so it cannot tell you which one did what. A written record is the closest you get.
- Before the first dose, write down the one goal you started for and how it stands today: a photo of the skin, how far the tendon bends before it hurts, or how often the gut flares.
- Check that same measure on the same day each week.
- Note anything new on the day it shows up, such as a reaction where the needle went in.
In PepVault, KLOW and GLOW are in the library as blends: the vial is one line, you type each part's dose yourself, and a note in the day's check-in stays with that day's doses. Track your vials in PepVault
Does KLOW or GLOW need cycling?
Nobody knows, because no study has tested it. Cycling means running a peptide for a set number of weeks and then pausing, and we found no study that compared cycling with continuous use, for either blend or for any of its four parts. The pages that give a firm answer either way are not quoting a trial.
What the studies do show is how long each part was given, and it is short. The rat tendon study ran four weeks1. For KPV there is no human study to time. In people, thymosin beta-4 was given by IV for 14 days18, as eye drops for 28 days1115 and as a skin gel for up to 56 days16. None ran for months, and none tested a second round after a break.
Community protocols commonly run the blends in 8 to 12 week stretches with a break between. That is a habit passed between users, not a tested schedule.
Are KLOW and GLOW approved, or allowed in sport?
Neither blend, and none of its four parts as an injection, is an FDA-approved drug. The FDA lists BPC-157, TB-500, KPV and injectable GHK-Cu among substances nominated for pharmacy compounding and later withdrawn. For each it notes a possible risk of immune reactions or impurities, or missing human data25.
For tested athletes, both blends are off limits at all times, because each holds two substances on the World Anti-Doping Agency's 2026 Prohibited List: BPC-157 under non-approved substances, and "Thymosin-β4 and its derivatives e.g. TB-500" under growth factors26.
Sources
- Biçer O et al. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: a histopathological and biomechanical study. Jt Dis Relat Surg. 2026. PubMed 42542926
- Lee E, Padgett B. Intra-articular injection of BPC 157 for multiple types of knee pain. Altern Ther Health Med. 2021. PubMed 34324435
- McGuire FP et al. Regeneration or risk? A narrative review of BPC-157 for musculoskeletal healing. Curr Rev Musculoskelet Med. 2025. PubMed 40789979
- Hsieh MJ et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017. PubMed 27847966
- Chang CH et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol. 2011. PubMed 21030672
- Malinda KM et al. Thymosin beta4 accelerates wound healing. J Invest Dermatol. 1999. PubMed 10469335
- Philp D et al. Thymosin beta 4 and a synthetic peptide containing its actin-binding domain promote dermal wound repair in db/db diabetic mice and in aged mice. Wound Repair Regen. 2003. PubMed 12581423
- Esposito S et al. Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential. Drug Test Anal. 2012. PubMed 22962027
- Rahaman KA et al. Simultaneous quantification of TB-500 and its metabolites in in-vitro experiments and rats by UHPLC-Q-Exactive orbitrap MS/MS and their screening by wound healing activities in-vitro. J Chromatogr B. 2024. PubMed 38382158
- Tham A, Hodgkins CW, Kennedy JG. Investigational peptides in orthopaedic practice: evidence, safety, and patient counseling for BPC-157, thymosin beta-4, and TB-500. J Am Acad Orthop Surg. 2026. PubMed 42937313
- Sosne G, Dunn SP, Kim C. Thymosin β4 significantly improves signs and symptoms of severe dry eye in a phase 2 randomized trial. Cornea. 2015. PubMed 25826322
- Sosne G, Ousler GW. Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, phase II clinical trial conducted using the controlled adverse environment (CAE) model. Clin Ophthalmol. 2015. PubMed 26056426
- ReGenTree. RGN-259 ophthalmic solutions for dry eye syndrome: ARISE-2 (NCT02974907), posted results. ClinicalTrials.gov. clinicaltrials.gov
- ReGenTree. RGN-259 ophthalmic solutions for dry eye syndrome: ARISE-3 (NCT03937882), posted results. ClinicalTrials.gov. clinicaltrials.gov
- Sosne G et al. 0.1% RGN-259 (thymosin ß4) ophthalmic solution promotes healing and improves comfort in neurotrophic keratopathy patients in a randomized, placebo-controlled, double-masked phase III clinical trial. Int J Mol Sci. 2022. PubMed 36613994
- RegeneRx Biopharmaceuticals. Thymosin beta 4 in patients with epidermolysis bullosa (NCT00311766), posted results. ClinicalTrials.gov. clinicaltrials.gov
- Guarnera G et al. The effect of thymosin treatment of venous ulcers. Ann N Y Acad Sci. 2010. PubMed 20536470
- Ruff D et al. A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta4 in healthy volunteers. Ann N Y Acad Sci. 2010. PubMed 20536472
- Maquart FX et al. Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+. FEBS Lett. 1988. PubMed 3169264
- Mulder GD et al. Enhanced healing of ulcers in patients with diabetes by topical treatment with glycyl-l-histidyl-l-lysine copper. Wound Repair Regen. 1994. PubMed 17147644
- Mokhtar J et al. The regenerative potential of GHK-Cu in aesthetic medicine. Aesthet Surg J. 2026. PubMed 42619529
- Dalmasso G et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008. PubMed 18061177
- Kannengiesser K et al. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflamm Bowel Dis. 2008. PubMed 18092346
- Xiao B et al. Orally targeted delivery of tripeptide KPV via hyaluronic acid-functionalized nanoparticles efficiently alleviates ulcerative colitis. Mol Ther. 2017. PubMed 28143741
- U.S. Food and Drug Administration. Certain bulk drug substances for use in compounding that may present significant safety risks (content current as of April 22, 2026). fda.gov
- World Anti-Doping Agency. The 2026 Prohibited List: S0 non-approved substances and S2.3 growth factors. wada-ama.org
Newsletter · Weekly
The weekly peptide briefing.
New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.